Francisco Morís

Learn More
Cancer initiating cells have been described to be the only cell population with tumorigenic capacity in glioblastoma multiforme, one of the most aggressive and untreatable cancers. Recent work from our group described that NFκB pathway was activated in glioblastoma initiating cells undergoing differentiation, and that blockade of this activation promoted(More)
Deregulated activity of transcription factors (TFs) of the Sp/KLF family, like Sp1, Sp3 and Sp4, and consequent over-expression of Sp-regulated genes occur frequently in human cancers. This provides the rationale for development of inhibitors of Sp TFs as cancer therapeutics. Mithramycin A (MTM-A) is a natural polyketide that binds GC-rich DNA sequences,(More)
Ovarian cancer has a poor prognosis due to intrinsic or acquired resistance to some cytotoxic drugs, raising the interest in new DNA-binding agents such as mithramycin analogues as potential chemotherapeutic agents in gynecological cancer. Using a genome-wide approach, we have analyzed gene expression in A2780 human ovarian carcinoma cells treated with the(More)
This paper provides a framework for translating research and development expenditure data organized based on the Frascati Manual to a measure of gross output consistent with The System of National Accounts 1993. This translation sets up the output measures and sectoral framework for the capitalization of R&D expenditures in a Satellite Account. members of(More)
Disclaimer Any opinions, findings, conclusions, or recommendations expressed in this workshop report are those of the participants and do not necessarily reflect the views of the National Science Foundation. Executive Summary The workshop "Advancing Measures of Innovation" was driven by recent calls for improvements in statistics on research and development(More)
Tumor initiating cells (TICs), responsible for tumor initiation, and cancer stem cells (CSCs), responsible for tumor expansion and propagation, are often resistant to chemotherapeutic agents. To find therapeutic targets against sarcoma initiating and propagating cells we used models of myxoid liposarcoma (MLS) and undifferentiated pleomorphic sarcoma (UPS)(More)
Mithramycin and chromomycin A(3) are two structurally related antitumour compounds, which differ in the glycosylation profiles and functional group substitutions of the sugars. Chromomycin contains two acetyl groups, which are incorporated during the biosynthesis by the acetyltransferase CmmA in Streptomyces griseus ssp. griseus. A bioconversion strategy(More)
Triple negative breast cancer (TNBC) is an aggressive form of breast cancer. Despite response to chemotherapy, relapses are frequent and resistance to available treatments is often observed in the metastatic setting. Therefore, identification of new therapeutic strategies is required. Here we have investigated the effect of the mithramycin analog EC-8042(More)
This paper translates research and development expenditure data organized based on the Frascati Manual for the U.S. to a measure of gross output consistent with The System of National Accounts 1993. A set of detailed tables translates U.S. survey data on the performance of R&D from the National Science Foundation for 2001. members of BEA staff for valuable(More)